PARMedics

[Not Yet Scheduled]
We are an early-stage biotech company developing small molecule antagonists to protease-activated-receptor-2 (PAR2) for treatment of pain and inflammation. Our team consists of 5 academic researchers, with decades of experience in PAR2 signaling, airway inflammation, pain and medicinal chemistry, as well as founding and successfully negotiating the acquisition of a biotech company. We are currently focusing on 3 major disease areas: migraine, chronic pain and asthma, that represent a large unmet need, a combined global market of $100 billion and a US market of $20 billion and cause an enormous economic burden of nearly $1 trillion in healthcare costs and lost productivity. Despite the existence of medications, nearly 50% of those affected with these diseases remain poorly controlled with standard of care. Our solution is the development of low cost small molecules for oral and inhaled administration to treat pain transmission and inflammation at their source.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
C781
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
PARMedics